53 results
8-K
EX-99.1
EYPT
EyePoint Pharmaceuticals Inc
5 Jun 23
EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathy
7:06am
–Significant investigator and patient interest drove strong recruitment of 77 patients exceeding the 60 patient target –
–Topline PAVIA data
8-K
EX-2.1
EYPT
EyePoint Pharmaceuticals Inc
18 May 23
EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties
7:06am
and reports (e.g., investigator brochures, informed consent forms, data safety monitoring board related documents, patient recruitment related
10-KT
EYPT
EyePoint Pharmaceuticals Inc
18 Mar 19
Annual report (with FYE transition)
5:30pm
period ended December 31, 2018 was highlighted by the following events:
We substantially completed recruitment of field-based regional sales, market … FDA approval for YUTIQ;
In July 2018, we began implementing an exclusive agreement with a contract sales organization (“CSO”) for the recruitment
8-K
EX-99.1
EYPT
EyePoint Pharmaceuticals Inc
14 Mar 19
Results of Operations and Financial Condition
7:00am
:
Recruitment and training of the Company’s field sales organization recently concluded, and the Company now has in place a44-person sales force (10 for YUTIQ